T1	Participants 116 154	advanced head and neck cancer patients
T2	Participants 498 565	first-line treatment of patients with advanced head and neck cancer
T3	Participants 598 762	patients with unresectable grade I/II head and neck cancer who were not suitable for irradiation treatment (T any N3 or T4 N2C), metastatic or previously irradiated
T4	Participants 899 911	170 patients
